top of page
MENU
MENU
News Release
"MIRX002" Achieves Primary Endpoint in Phase I Clinical Trial for Malignant Pleural Mesothelioma
PURMX Therapeutics, Inc. (Headquartered in Hiroshima, Japan; President and CEO: Hidetoshi Tahara; hereinafter "the Company") is pleased to announce the completion of both the Single Ascending Dose (SAD) study (Protocol No.: MIRX002-01) and the Multiple Ascending Dose (MAD) study (Protocol No.: MIRX002-02), investigator-initiated clinical trials for malignant pleural mesothelioma using natural-type microRNA replacement therapy, for which the Company supplied the investigationa
May 27
PURMX Therapeutics Selected as an Awardee of the Japan Smart Healthy Aging QuickFire Challenge
PURMX Therapeutics, Inc. (Headquarters: Hiroshima-city, Hiroshima; President & CEO: Hidetoshi Tahara) is pleased to announce that it has...
Sep 8, 2025
PURMX Therapeutics Receives Orphan Drug Designation for miR-3140-3p from the U.S. FDA
PURMX Therapeutics Inc. (hereinafter “PURMX”), headquartered in Hiroshima, Japan and led by President and CEO Hidetoshi Tahara, announced...
May 9, 2025
bottom of page